Vicore announced the successful completion of the Phase I dose-escalation study for lead candidate VP01 (C21), its first in class, orally available angiotensin II type 2 receptor (“AT2R”) agonist. The trial identified the maximum tolerated dose (“MTD”), which has a good safety profile, therefore paving the way for the start of two Phase IIa proof-of-concept (“PoC”) trials in idiopathic pulmonary fibrosis (“IPF”) and diffuse systemic sclerosis (“dSSc”) later this year. The study also yielded two ....
09 Sep 2019
Successful VP01 Phase I identifies Phase IIa dose
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful VP01 Phase I identifies Phase IIa dose
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
09 Sep 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Vicore announced the successful completion of the Phase I dose-escalation study for lead candidate VP01 (C21), its first in class, orally available angiotensin II type 2 receptor (“AT2R”) agonist. The trial identified the maximum tolerated dose (“MTD”), which has a good safety profile, therefore paving the way for the start of two Phase IIa proof-of-concept (“PoC”) trials in idiopathic pulmonary fibrosis (“IPF”) and diffuse systemic sclerosis (“dSSc”) later this year. The study also yielded two ....